Literature DB >> 28323987

Fibroblast Growth Factor 23, Mineral Metabolism, and Adiposity in Normal Kidney Function.

Sarah Zaheer1, Ian H de Boer2, Matthew Allison3, Jenifer M Brown1, Bruce M Psaty4,5, Cassianne Robinson-Cohen2,6, Erin D Michos7, Joachim H Ix8, Bryan Kestenbaum2,6, David Siscovick9, Anand Vaidya1.   

Abstract

Context: Obesity is associated with poor bone mineralization and quality. Fibroblast growth factor 23 (FGF23) plays an important role in skeletal physiology. Objective: To test hypothesis that greater adiposity results in higher FGF23 levels among individuals with normal estimated glomerular filtration rate (eGFR). Design, Setting, Participants: Cross-sectional analyses among participants with eGFR ≥60 mL/min/1.73m2. We assessed the association between crude [body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR); n = 5610] and refined (abdominal adipose tissue area by computed tomography; n = 1313) measures of adiposity and FGF23 using multivariable linear regression. Main Outcome Measure: Serum FGF23.
Results: FGF23 was higher across BMI categories (BMI <25: 37.7; BMI 25 to 29.99: 38.7; BMI 30 to 39.99: 39.8; BMI ≥40: 40.9 pg/mL, unadjusted P trend < 0.0001). The association between BMI and FGF23 was independent of known confounders of FGF23 (adjusted β = +7.2% higher FGF23 per 10 kg/m2; P < 0.0001). Similar results were observed using WC and WHR. Abdominal adipose tissue area was also independently associated with higher FGF23 (P < 0.01). Notably, the positive associations between FGF23 and adiposity were observed despite the fact that eGFR did not decline and serum phosphate levels did not increase with adiposity.
Conclusion: In a large cohort with normal kidney function, adiposity was associated with higher FGF23 levels independent of known confounders, including eGFR and phosphate. Further studies are needed to evaluate the causes of higher FGF23 in settings of greater adiposity and the potential impact on skeletal health.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28323987      PMCID: PMC5460732          DOI: 10.1210/jc.2016-3563

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

1.  Obesity is not protective against fracture in postmenopausal women: GLOW.

Authors:  Juliet E Compston; Nelson B Watts; Roland Chapurlat; Cyrus Cooper; Steven Boonen; Susan Greenspan; Johannes Pfeilschifter; Stuart Silverman; Adolfo Díez-Pérez; Robert Lindsay; Kenneth G Saag; J Coen Netelenbos; Stephen Gehlbach; Frederick H Hooven; Julie Flahive; Jonathan D Adachi; Maurizio Rossini; Andrea Z Lacroix; Christian Roux; Philip N Sambrook; Ethel S Siris
Journal:  Am J Med       Date:  2011-11       Impact factor: 4.965

2.  Are general obesity and visceral adiposity in men linked to reduced bone mineral content resulting from normal ageing? A population-based study.

Authors:  E A Jankowska; E Rogucka; M Medraś
Journal:  Andrologia       Date:  2001-11       Impact factor: 2.775

3.  Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis.

Authors:  Yi Fan; Ruiye Bi; Michael J Densmore; Tadatoshi Sato; Tatsuya Kobayashi; Quan Yuan; Xuedong Zhou; Reinhold G Erben; Beate Lanske
Journal:  FASEB J       Date:  2015-10-01       Impact factor: 5.191

4.  Visceral adiposity and the risk of metabolic syndrome across body mass index: the MESA Study.

Authors:  Ravi V Shah; Venkatesh L Murthy; Siddique A Abbasi; Ron Blankstein; Raymond Y Kwong; Allison B Goldfine; Michael Jerosch-Herold; João A C Lima; Jingzhong Ding; Matthew A Allison
Journal:  JACC Cardiovasc Imaging       Date:  2014-11-05

5.  Expression of Fgf23 in activated dendritic cells and macrophages in response to immunological stimuli in mice.

Authors:  Yuki Masuda; Hiroya Ohta; Yumiko Morita; Yoshiaki Nakayama; Ayumi Miyake; Nobuyuki Itoh; Morichika Konishi
Journal:  Biol Pharm Bull       Date:  2015-02-26       Impact factor: 2.233

6.  Up-regulation of FGF23 release by aldosterone.

Authors:  Bingbing Zhang; Anja T Umbach; Hong Chen; Jing Yan; Hajar Fakhri; Abul Fajol; Madhuri S Salker; Daniela Spichtig; Arezoo Daryadel; Carsten A Wagner; Michael Föller; Florian Lang
Journal:  Biochem Biophys Res Commun       Date:  2016-01-08       Impact factor: 3.575

7.  Obesity and fractures in postmenopausal women.

Authors:  Melissa Orlandin Premaor; Lesley Pilbrow; Carol Tonkin; Richard A Parker; Juliet Compston
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

8.  Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Bryan Kestenbaum; Michael C Sachs; Andy N Hoofnagle; David S Siscovick; Joachim H Ix; Cassianne Robinson-Cohen; Joao A C Lima; Joseph F Polak; Marc Blondon; John Ruzinski; Denise Rock; Ian H de Boer
Journal:  Circ Heart Fail       Date:  2014-03-25       Impact factor: 8.790

9.  Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo.

Authors:  Yumie Rhee; Nicoletta Bivi; Emily Farrow; Virginia Lezcano; Lilian I Plotkin; Kenneth E White; Teresita Bellido
Journal:  Bone       Date:  2011-06-25       Impact factor: 4.398

10.  The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women.

Authors:  M Holecki; J Chudek; A Więcek; M Titz-Bober; J Duława
Journal:  Int J Endocrinol       Date:  2011-11-24       Impact factor: 3.257

View more
  7 in total

1.  Parathyroid Hormone and Plasma Phosphate Are Predictors of Soluble α-Klotho Levels in Adults of European Descent.

Authors:  Nasser A Dhayat; Menno Pruijm; Belen Ponte; Daniel Ackermann; Alexander Benedikt Leichtle; Olivier Devuyst; Georg Ehret; Idris Guessous; Antoinette Pechère-Bertschi; Johanne Pastor; Pierre-Yves Martin; Michel Burnier; Georg-Martin Fiedler; Bruno Vogt; Orson W Moe; Murielle Bochud; Daniel G Fuster
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Sleep disordered breathing and fibroblast growth factor 23 in the Hispanic Community Health Study/Study of Latinos.

Authors:  Rupal Mehta; Xuan Cai; Alexander Hodakowski; Bharat Thyagarajan; Donglin Zeng; Phyllis C Zee; William K Wohlgemuth; Susan Redline; James P Lash; Myles Wolf; Tamara Isakova
Journal:  Bone       Date:  2018-07-03       Impact factor: 4.398

3.  Association of FGF19, FGF21 and FGF23 with carbohydrate metabolism parameters and insulin resistance in patients with chronic kidney disease.

Authors:  Malgorzata Marchelek-Mysliwiec; Violetta Dziedziejko; Katarzyna Dolegowka; Andrzej Pawlik; Krzysztof Safranow; Joanna Stepniewska; Magda Wisniewska; Jolanta Malyszko; Kazimierz Ciechanowski
Journal:  J Appl Biomed       Date:  2020-02-28       Impact factor: 1.797

4.  Fibroblast Growth Factor 23 is Associated With Adiposity in Patients Receiving Hemodialysis: Possible Cross Talk Between Bone and Adipose Tissue.

Authors:  Janet M Chiang; George A Kaysen; Anne L Schafer; Cynthia Delgado; Kirsten L Johansen
Journal:  J Ren Nutr       Date:  2018-03-29       Impact factor: 3.655

5.  The Effect of a Comprehensive Life-Style Intervention Program of Diet and Exercise on Four Bone-Derived Proteins, FGF-23, Osteopontin, NGAL and Sclerostin, in Overweight or Obese Children and Adolescents.

Authors:  Sofia I Karampatsou; George Paltoglou; Sofia M Genitsaridi; Penio Kassari; Evangelia Charmandari
Journal:  Nutrients       Date:  2022-09-13       Impact factor: 6.706

6.  High phosphate diet suppresses lipogenesis in white adipose tissue.

Authors:  Yukiko Imi; Norie Yabiki; Maerjianghan Abuduli; Masashi Masuda; Hisami Yamanaka-Okumura; Yutaka Taketani
Journal:  J Clin Biochem Nutr       Date:  2018-07-11       Impact factor: 3.114

7.  Serum Phosphate, BMI, and Body Composition of Middle-Aged and Older Adults: A Cross-Sectional Association Analysis and Bidirectional Mendelian Randomization Study.

Authors:  Ariadne Bosman; Natalia Campos-Obando; Carolina Medina-Gomez; Trudy Voortman; André G Uitterlinden; M Carola Zillikens
Journal:  J Nutr       Date:  2022-01-11       Impact factor: 4.798

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.